RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
   Small Cell Carcinoma
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Lung Channel

subscribe to Lung newsletter
Latest Research : Cancer : Lung

   EMAIL   |   PRINT
Aerosolized Cyclosporine Shows Significant Results in Chronic Rejection of Allogenic Lung Transplants

Mar 24, 2005 - 9:22:00 AM
The aerosolized cyclosporine NDA (50-799) includes a single pivotal trial that showed significant results in chronic rejection of allogenic lung transplants, but not in acute rejection.

 
[RxPG] The Pulmonary-Allergy Drugs Advisory Committee will review Chiron’s aerosolized cyclosporine Pulminiq for lung transplantation June 6.

The committee discussion likely will focus on additional analyses of pivotal data.

Chiron confirmed that FDA extended aerosolized cyclosporine’s priority review deadline of April 15 by 90 days following the firm’s submission of additional analyses earlier this year.

The company had been expecting the 90-day extension following FDA’s request for further analysis of the NDA’s pivotal trial.

The aerosolized cyclosporine NDA (50-799) includes a single pivotal trial that showed significant results in chronic rejection of allogenic lung transplants, but not in acute rejection.

Chiron is seeking approval for use of aerosolized cyclosporine in combination with standard immunosuppressive therapy to increase survival and prevent chronic rejection in patients receiving allogenic lung transplants.

This would be the first immunosuppresant approved for the indication, Chiron said.



Publication: FDA Advisory Committee
On the web: FDA Advisory Committee 

Advertise in this space for $10 per month. Contact us today.


Related Lung News
Tamoxifen reduces mortality rate in lung cancer
Lung Cancer risk greater in tuberculosis patients
Genes to identify patients who would benefit from chemotherapy
First-line treatment with erlotinib improved progression-free survival in advanced lung cancer
Genetic variation-Lung cancer drugs work better in the Japanese than in the Americans
Ireland Cancer Center researchers advance lung cancer treatment
Lung cancer screening regimen provides opportunity for cure
MEK inhibitors may be beneficial for lung cancer containing mutations in the BRaf gene
Potential solution to cetuximab-resistance in lung cancers
Gene Expression Profiling Not Quite Perfected in Predicting Lung Cancer Prognosis

Subscribe to Lung Newsletter

Enter your email address:


 Additional information about the news article
This meeting will be held June 6, 2005 at the CDER advisory committee conference room in Rockville, Md. beginning at 8 a.m.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)